摘要: Recent developments in the prosecution of CRISPR-Cas9 patent Europe highlight differences between intellectual property regimes and United States.
nature.com
sci-hub.se 参考文章(5)
Cormac Sheridan, First CRISPR-Cas patent opens race to stake out intellectual property. Nature Biotechnology. ,vol. 32, pp. 599- 601 ,(2014) , 10.1038/NBT0714-599
M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, E. Charpentier, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. ,vol. 337, pp. 816- 821 ,(2012) , 10.1126/SCIENCE.1225829
Patrick D. Hsu, Eric S. Lander, Feng Zhang, Development and applications of CRISPR-Cas9 for genome engineering. Cell. ,vol. 157, pp. 1262- 1278 ,(2014) , 10.1016/J.CELL.2014.05.010
Feng Zhang, CRISPR-Cas systems and methods for altering expression of gene products ,(2013)
Romuald Singer, Margarete Singer, Ralph Lunzer, European patent convention Published in <b>1995</b> in London by Sweet and Maxwell. ,(1995)